1 results match your criteria: "Assiut University Assiut 71526 Egypt bgyoussif2@gmail.com +20-01098294419.[Affiliation]"
Design, synthesis, and biological evaluation of novel quinoline-based EGFR/HER-2 dual-target inhibitors as potential anti-tumor agents.
RSC Adv
October 2024
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Assiut University Assiut 71526 Egypt +20-01098294419.
Article Synopsis
- Dual-targeting EGFR and HER2 is an effective method for treating solid tumors, leading researchers to develop new quinoline-based inhibitors.
- The synthesized compounds were tested on multiple cancer cell lines, showing GI values from 25 to 82 nM, with compound 5a being the most effective against breast and lung cancer cells.
- Compound 5a not only outperformed the EGFR inhibitor erlotinib but also demonstrated potential in promoting cell apoptosis by activating certain proteins while inhibiting others, along with docking studies that clarified its binding with EGFR.